User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

3453

Interactions with Platform & by Email *

INTERACTIONS

622

Unique # Participated *

PARTICIPANTS

104

Responses Validated *

VALIDATIONS

30

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Stats to Ponder At.....II-11$100
   Ovarian Cancer Therapeutics Market – Current & Future Analysis.....II-2
Ovarian Cancer Therapeutics Market Propelled by the High Relapse Rates.....II-2
Hopes Set On Emerging Immunotherapeutics.....II-2
MAbs to Rule the Market.....II-2
1$100
   Next Gen Therapeutics to Watch Out For.....II-3
GOG Commences Phase III Trial of XYOTAX(TM).....II-3
InterMune Completes Enrollment of Pivotal Phase III Trial of Actimmune.....II-3
Antisoma Concludes Phase III Trials of Pemtumomab.....II-3
1$100
   Genentech to Initiate Phase III Trials of Avastin.....II-4
Advaxis Seeks Partner for LOVAXIN NY Vaccine.....II-4
Alethia Hunts Worldwide Partner for Ovarian Cancer Therapy.....II-4
Other Therapeutic Drugs in the Pipeline.....II-4
1$100
   Types of Ovarian Cancer.....II-5
Epithelial Ovarian Tumors.....II-5
Germ-Cell Tumors.....II-5
Stromal Tumors.....II-5
1$100
   Symptoms.....II-6
Clinical Stages And Grades In Ovarian Cancer.....II-6
Stage I.....II-6
1$100
   Stage IA.....II-7
Stage IB.....II-7
Stage IC.....II-7
Stage II.....II-7
Stage IIA.....II-7
Stage IIB.....II-7
Stage IIC.....II-7
Stage III.....II-7
Stage IIIA.....II-7
Stage IIIB.....II-7
Stage IIIC.....II-7
Stage IV.....II-7
1$100
   Risk Factors.....II-81$100
   Preventive Measures.....II-9
Inhibiting Ovulation.....II-9
1$100
   Ligation of Fallopian Tubes.....II-10
Prophylactic Oophorectomy.....II-10
Lifestyle Factors.....II-10
Detection.....II-10
1$100
   Rectal and Pelvic Examination.....II-11
Ultrasound Screening.....II-11
CA-125 Blood Test.....II-11
CAT/CT Scan (Computerized Axial Tomography Scan).....II-11
Laparotomy.....II-11
1$100
   Ovarian Pap Test.....II-12
Modes of Treatment.....II-12
Surgery.....II-12
1$100
   Chemotherapy.....II-131$100
   Radiation Therapy.....II-141$100
   Clinical Trials (Treatment Studies).....II-15
1$100
   Immunotherapy.....II-16
Gene Therapy.....II-16
Antiangiogenesis Agents.....II-16
Retinoids.....II-16
1$100
   Imatinib .....II-17
LH-RH Agonists.....II-17
Epothilones.....II-17
Aromatase Inhibitors.....II-17
Matripase Inhibitors.....II-17
Intraperitoneal Chemotherapy.....II-17
1$100
   High Dose Chemotherapy.....II-18
1$100
   Stage IA .....II-19
Stage IB .....II-19
Stage IC .....II-19
Stage IIA.....II-19
1$100
   Stages IIB, IIIA, IIIB, IIIC and IV.....II-20
1$100
   Altretamine.....II-21
Capecitabine.....II-21
Carboplatin.....II-21
1$100
   Cisplatin.....II-22
Cyclophosphamide.....II-22
Docetaxel.....II-22
Doxorubicin.....II-22
1$100
   Etoposide.....II-23
Gemcitabine.....II-23
Ifosfamide.....II-23
Irinotecan.....II-23
Melphalan.....II-23
1$100
   Paclitaxel.....II-24
Pegylated Liposomal Doxorubicin.....II-24
Tamoxifen.....II-24
Topotecan.....II-24
Valspodar.....II-24
1$100
   Vinorelbine.....II-25
1$100
   Localized Ovarian Cancer Therapeutics.....II-26
Metastatic Ovarian Cancer Therapeutics.....II-26
1$100
   Relapsed Ovarian Cancer Therapeutics.....II-27
2$200
   VEGF Fuels Tumor Angiogenesis.....II-29
List of Modified Taxanes is Escalating.....II-29
FHCRC Tries to Identify Novel Genes.....II-29
Combined Administration of Different Drugs is Fruitful.....II-29
1$100
   Women are at Risk with Estrogen Therapy.....II-30
Tools to Visualize Disease Progress.....II-30
Treatment for Ovarian Cancer – The Titanium Way.....II-30
HSV Therapy for Advanced Ovarian Cancer.....II-30
1$100
   Oxford BioMedica Halts Development of Gene Therapy for Ovarian Cancer.....II-31
ImmunoGen, Raven Biotechnologies Agreement Over Ovarian Cancer Therapy Expires.....II-31
TopoTarget Commences PXD 101 Phase I Trials.....II-31
AmpliMed’s Imexon Orphan Drug Gets US FDA Grant.....II-31
DOXIL Obtains FDA Stamp of Approval.....II-31
1$100
   Cell Therapeutics Enters into Agreement with Gynecologic Oncology Group.....II-32
Raven Biotechnologies Enters into Research Collaboration with Abbott
  Laboratories.....II-32
Ivax Gets Endorsement from European Commission for Commercializing its Generic Form of
  Paclitaxel.....II-32
Bristol and Pierre Fabre Médicament Sign Agreement.....II-32
AltaRex Enters into a Licensing Agreement with United Therapeutics.....II-32
1$100
   Nippon Kayaku and GlaxoSmithKline Enter into an Agreement.....II-33
Roche to Purchase Antisoma Drugs.....II-33
ImmunoGen and Raven Biotechnologies Enter into Collaboration.....II-33
Pemtumomab Receives European Orphan Drug Status.....II-33
Immusol, Inc, Discovers ID4 Drug Target Gene for Breast & Ovarian Cancer.....II-33
ALZA'S CAELYX® Receives Endorsement from Canadian Therapeutic Products
  Programme.....II-33
1$100
   GlaxoSmithKline’s Hycamtin Receives Endorsement from UK National Institute for Clinical
  Excellence.....II-34
1$100
   Alza Corporation (US).....II-35
Amgen Inc. (US).....II-35
Bristol-Myers Squibb (US).....II-35
1$100
   Cell Therapeutics Inc. (US).....II-36
Genentech, Inc. (US).....II-36
GlaxoSmithkline Plc (UK).....II-36
1$100
   Immunogen Inc. (US).....II-37
Ivax (US).....II-37
OSI Pharmaceuticals (US).....II-37
Raven Biotechnologies Inc. (US).....II-37
1$100
   Table 1: World Recent Past, Current & Future Analysis for Ovarian Cancer Therapeutics Market by Geographic Region – US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graphs/Chart).....II-38

Table 2: World 10-Year Perspective for Ovarian Cancer Therapeutics Market by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for Years 2000, 2005 & 2010 (includes corresponding Graphs/Chart).....II-38
1$300
   A. Market Analysis.....III-1
Current & Future Analysis.....III-1
Prevalence in the US.....III-1
Table 3: Estimated Cancer Cases by Site Among Women in the US: 2004 (includes corresponding Graphs/Chart).....III-1
1$150
   Table 4: Estimated Cancer Deaths by Site Among Women in the US : 2004 (includes corresponding Graphs/Chart).....III-2
Associated Ovarian Cancer Therapeutics Developments.....III-2
1$150
   Strategic Corporate Developments.....III-32$150
   Focus on Key Players.....III-5
Alza Corporation.....III-5
Amgen Inc......III-5
Bristol-Myers Squibb.....III-5
1$75
   Cell Therapeutics Inc......III-6
Genentech, Inc......III-6
Immunogen Inc.....III-6
Ivax.....III-6
1$75
   OSI Pharmaceuticals.....III-7
Raven Biotechnologies Inc......III-7
Medarex Inc......III-7
1$75
   B. Market Analytics.....III-8
Table 5: US Recent Past, Current & Future Analysis for Ovarian Cancer Therapeutics Market by Product Segments – Localized Ovarian Cancer Therapeutics, Metastatic Ovarian Cancer Therapeutics, Refractory Ovarian Cancer Therapeutics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graphs/Chart).....III-8

Table 6: US 10-Year Perspective for Ovarian Cancer Therapeutics by Market Product Segments– Percentage Breakdown of Dollar Sales for Localized Ovarian Cancer Therapeutics, Metastatic Ovarian Cancer Therapeutics, Refractory Ovarian Cancer Therapeutics Markets for Years 2000, 2005 & 2010 (includes corresponding Graphs/Chart).....III-8
1$150
   A. Market Analysis.....III-9
Current and Future Analysis.....III-9
Ovarian Cancer Stats.....III-9
B. Market Analytics.....III-9
Table 7: Canadian Recent Past, Current & Future Analysis for Ovarian Cancer Therapeutics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graphs/Chart).....III-9
1$150
   A. Market Analysis.....III-10
Current and Future Analysis.....III-10
B. Market Analytics.....III-10
Table 8: Japanese Recent Past, Current & Future Analysis for Ovarian Cancer Therapeutics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graphs/Chart).....III-10
1$150
   A. Market Analysis.....III-11
Current and Future Analysis.....III-11
Incidence of Ovarian Cancer.....III-11
Table 9: Ovarian Cancer Incidence in Europe by Geographic Region for 2002: France, Germany, Russia, UK, Italy and Spain (includes corresponding Graphs/Chart).....III-11
Strategic Corporate Developments.....III-11
2$300
   GlaxoSmithkline Plc - A Key Player.....III-13
B. Market Analytics.....III-13
Table 10: European Recent Past, Current & Future Analysis for Ovarian Cancer Therapeutics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graphs/Chart).....III-13
1$150
   A. Market Analysis.....III-14
Current and Future Analysis.....III-14
Table 11: Ovarian Cancer Incidence in Major Countries in Asia-Pacific: 2002 (includes corresponding Graphs/Chart).....III-14

Table 12: Ovarian Cancer Incidence in Major Countries in Latin America: 2002 (includes corresponding Graphs/Chart).....III-14
1$150
   Table 13: Ovarian Cancer Incidence in Major Countries in Middle East: 2002 (includes corresponding Graphs/Chart).....III-15

Table 14: Ovarian Cancer Incidence in Major Countries in Africa :2002 (includes corresponding Graphs/Chart).....III-15
B. Market Analytics.....III-15
Table 15: Rest of World Recent Past, Current & Future Analysis for Ovarian Cancer Therapeutics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graphs/Chart).....III-15
1$150
    
 
 


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com